On March 12th, the "Zhongguancun Science City Innovation Drug Internationalization Seminar" was successfully held under the guidance of the Zhongguancun Science City Management Committee, hosted by Zhongguancun Science City Company and the International Pharmaceutical Enterprise Alliance Association, and jointly organized by Haixinyu Urban Renewal Group, Ziyi Law Firm, Chaosheng Beijing Laboratory, and Baifang Yingku. Leaders such as Lin Hang, Deputy District Mayor of Haidian District, attended the event.

　　This event focuses on the field of innovative drugs, with the theme of "Thousand Sails Competing, Embracing the Global Wave of Innovative Drugs Together". It invites nearly a hundred guests from international top pharmaceutical companies and more than 30 representative enterprises of innovative drugs in Haidian District to attend. Weidejie Biotechnology, as a representative enterprise of innovative drugs, attended the conference.

　　During the visit and visitation process, leaders such as Lin Hang, Deputy District Mayor of Haidian District, and representatives of overseas enterprises visited Area A of Haixing Pharmaceutical Health Innovation Park, visited industry service platforms such as Baifang Incubator and Chaosheng Accelerator, as well as innovative drug representative enterprise Weidejie, to understand the cultivation of the innovative drug industry in Haidian District.

　　Li Ziqiang, founder of Weidejie, introduced the company's layout and technological advantages in the field of innovative antibody drugs for autoimmune diseases to the guests. The leaders and guests on site fully affirmed Weidejie Biotechnology's development in the field of innovative drugs.

　　After the visit and exchange, the seminar will be held in Zone C of Haixing Medical and Health Innovation Park. The meeting was chaired by Dai Lian, Deputy General Manager of Beijing Zhongguancun Science City Innovation and Development Co., Ltd. Firstly, Deputy District Mayor Lin Hang delivered a speech, stating that Haidian District, relying on the advantages of universities, institutions, and clinical resources, vigorously develops the pharmaceutical and health industry, gathers more than 500 high-tech enterprises, and has achieved technological breakthroughs in areas such as cell gene therapy, recombinant proteins, ADC drugs, etc. As a major intellectual property region, Haidian District attaches great importance to the protection of intellectual property rights for technological achievements represented by innovative drugs. With the support of local political and legal institutions and social organizations, a comprehensive intellectual property protection system has been established. In terms of industrial services, a service chain with "incubator accelerator service platform industrial park" as the carrier has been formed, effectively supporting the rapid growth of innovative drug enterprises in the area. Haidian District hopes to strengthen cooperation with leading pharmaceutical companies and promote new growth and transformation of the innovative pharmaceutical industry in Haidian District.

　　During the keynote speech and discussion session, representatives from innovative pharmaceutical companies in Haidian District introduced the development history of innovative drugs in China, showcased innovative achievements and technological breakthroughs in the forefront technology field of innovative drugs, and conducted in-depth discussions on various aspects such as overseas trends and models, and exploration of innovative strategies for overseas layout. The discussion atmosphere at the conference was lively.

　　The successful holding of the Zhongguancun Science City Innovation Drug Internationalization Seminar has effectively built a communication and exchange bridge between international leading pharmaceutical companies and innovative pharmaceutical companies in Haidian District. Weidejie Biotechnology will use its core technology to help the high-quality development of the innovative pharmaceutical industry in Haidian District, breaking the situation of the lack of independent innovative drugs in the field of self exemption and long-term dependence on imports.